Outpace Bio
AI-powered engineered proteins for enhanced CAR-T cell therapy
- Sector
- Biotech
- Headquarters
- SEATTLE, WA
- Founded
- 2020
- Latest Form D
- $56M, Aug 2024
- Total capital
- $56M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $56M
- 1 Form D · last Aug 2024
- 27 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 40 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$56M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Aaron FosterExecutive OfficerNamed in SEC Form D filings
- Bahija JallalDirectorNamed in SEC Form D filings
- Charity ScriptureExecutive OfficerNamed in SEC Form D filings
- Eric SollerExecutive OfficerNamed in SEC Form D filings
- Jake SimsonDirectorNamed in SEC Form D filings
- Marc LajoieExecutive Officer, Director, PromoterNamed in SEC Form D filings
Show all 8 people
- Scott BoykenExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Vasudev BaileyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 40- PendingSmall Molecule-regulated Cell Signaling Expression SystemUSPTOApplication 18274944
- PendingDesigned Cytokine Compositions And Methods Of UseUSPTOApplication 18727646
- PendingChimeric Antigen ReceptorsUSPTOApplication 18708558
Show all 40 patent records
- Small Molecule-regulated Cell Signaling Expression SystemAug 28, 2025 · Application 18274944Pending
- Designed Cytokine Compositions And Methods Of UseJul 10, 2025 · Application 18727646Pending
- Chimeric Antigen ReceptorsJan 9, 2025 · Application 18708558Pending
- Chimeric PolypeptidesMay 25, 2023 · Application 17812712Pending
- Anti-mesothelin Chimeric Antigen Receptors And Methods Of UseApplication 63670688Pending
- CD8 Binding Polypeptides And Methods Of UseApplication 63670723Pending
- Designed Cytokine Compositions And Methods Of UseApplication PCTUS2024037942Pending
- Inducible ConstructsApplication PCTUS2024010926Pending
- Anti-mesothelin Chimeric Antigen Receptors And Methods Of UseApplication 63582826Pending
- Anti-exhaustion Compositions And Methods Of Use Thereof In T-cellsApplication 63582819Pending
- Designed Cytokine Compositions And Methods Of UseApplication 63513540Pending
- Targeted IL-12 Affinity VariantsApplication 63526405Pending
- IL-12 Stability VariantsApplication 63510579Pending
- Synthetic Degrader System For Targeted Protein DegradationApplication PCTUS2023061890Pending
- Designed Cytokine Compositions And Methods Of UseApplication PCTUS2023060508Pending
- Inducible Promoter And Enhancer Combination ConstructsApplication 63479178Pending
- Inducible ConstructsApplication 63479176Pending
- Inducible Receptor SystemsApplication 63479177Pending
- Targeted IL-12 Affinity VariantsApplication 63478935Pending
- Chimeric Antigen ReceptorsApplication PCTUS2022049611Pending
- Synthetic Degrader System for Targeted Protein DegradationApplication 63312818Pending
- Chimeric Antigen ReceptorsApplication 63307612Pending
- Inducible ConstructsApplication 19146468Pending
- Synthetic Degrader System for Targeted Protein DegradationApplication 63306078Pending
- Synthetic Degrader System For Targeted Protein DegradationApplication PCTUS2022014998Pending
- Synthetic Degrader System for Targeted Protein DegradationApplication 63306075Pending
- Small Molecule-regulated Cell Signaling Expression SystemApplication PCTUS2022014624Pending
- Small Molecule-regulated Gene Expression SystemApplication PCTUS2022012688Pending
- Redesigned IL-2 Cytokine Compositions and Methods of UseApplication 63298623Pending
- IL-12 Affinity VariantsApplication 63297666Pending
- Chimeric Antigen ReceptorsApplication 63277984Pending
- Synthetic degrader system for targeted protein degradationApplication 63248516Pending
- Small molecule-regulated gene expression systemApplication 63164866Pending
- Modulating protein function in cells through designed targeted degradersApplication 63144895Pending
- Inducible expression systemsApplication 63143735Pending
- CD8 Binding Polypeptides And Methods Of UseApplication PCTUS2025037399Pending
- Chimeric PolypeptidesApplication PCTUS2021014767Pending
- Synthetic Degrader System For Targeted Protein DegradationApplication 18275585Pending
- Anti-exhaustion Compositions And Methods Of Use ThereofApplication 19518797Pending
- Designed INTERLEUKIN-2 Cytokine Compositions And Methods For UseApplication 19501926Pending
Related companies, and why
- iToleranceSimilar federal contract value in Biotech · null in contracts
- IZUN PHARMACEUTICALS CORPSimilar federal contract value in Biotech · null in contracts
- Alterome TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Chemomab Therapeutics Ltd.Similar federal contract value in Biotech · null in contracts
- Lumena Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Mosaic Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .